aXess is a restorative arteriovenous dialysis conduit which allows vascular access for hemodialysis through the creation of a new, permanent, living vessel
Read more
Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, today announces t...
Read more
Memo Therapeutics, a late-stage biotech company developing a best-in-class BKV-neutralizing antibody for BKV infection in kidney transplantation, today announces that it has successfully raised CHF 20...
Read more
Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced the close o...
Read more
NorthSea Therapeutics B.V. today announced the dosing of the first patient in its Phase 2a clinical trial of Orziloben (NST-6179) in intestinal failure-associated liver disease (IFALD), an orphan live...
Read more
Proceeds from the financing will be used to advance the company’s pipeline of wholly-owned, off-the-shelf cell therapies for multiple indications, including its lead investigational candidate, NRTX-...
Read more
Source BioScience, an industry-leading provider of genomic services and healthcare diagnostics, and Inbiomotion, a company commercializing its proprietary MAF Test® for identifying high risk early-st...
Read more
Vivet Therapeutics announces the financing of EUR 4.9 million received from the French government to advance the development of a gene therapy for the treatment of cerebrotendinous xanthomatosis (CTX)...
Read more
Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC
Read more
SparingVision today announces a key advancement in its Phase I/II clinical trial for SPVN06, the Company’s lead gene-agnostic investigational gene therapy for the treatment of retinitis pigmentosa (...
Read more
This pioneering test aids oncologists in predicting recurrence and survival rates in breast cancer patients and potential treatment eligibility to bisphosphonates
Read more
As part of CALYX, Minoryx is conducting an extensive pre-screening MRI-based campaign aimed at identifying eligible adult X-ALD patients with cerebral Adrenoleukodystrophy (cALD)
Read more
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
Telum Therapeutics, a biotechnology company leveraging proprietary met...
